CorMedix Inc. to Present at the Cantor Global Healthcare Conference

BERKELEY HEIGHTS, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that management will be participating in a fireside chat and investor meetings at the 2024 Cantor Healthcare Conference, being held in New York, NY on September 17 – 19, 2024.

Cantor Global Healthcare Conference

Date:   Thursday, September 19, 2024
Time:   10:55AM EDT
Format:   Fireside Chat and 1×1 Meetings
Webcast:   Click Link
     

A replay of the fireside chat will also be available in the “Events and Presentations” page on the investor relations portion of the Company’s website at: www.cormedix.com

About CorMedix

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath®, which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix also intends to develop DefenCath as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com.

Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576

Staff

Recent Posts

Oracle Supports the Veteran Interoperability Pledge

Oracle Health delivers free code to enable organizations to securely access a Veteran's health history…

3 hours ago

Charles River Comparative Study Reveals that Kytopen’s Flowfect Tx™ Platform Outperforms Conventional Electroporation Platforms

Charles River generated best-in-class data with Kytopen's Flowfect™ technology in comparative study.The study using CRISPR/Cas9…

3 hours ago

HDT Bio to Help Spearhead RNA Vaccine Development in National Pandemic Preparedness Initiative

HDT bio's Rapid-Response Roadmap for RNA vaccines (R4) project granted a five-year subaward for $2M…

3 hours ago

BioLineRx Launches ‘Mobilization Matters’: A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection

Patient survey currently underway in partnership with the HealthTree Foundation; data expected in Q1 2025 TEL AVIV, Israel and WALTHAM, Mass., Sept.…

3 hours ago